This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks the Pros Love This Summer

Celgene

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Biopharmaceutical firm Celgene ( CELG) is enjoying some stellar performance in 2013. Shares of the $50 billion name have rallied more than 53% since the calendar flipped over to 2013. A lot of the firm's success can be traced to the success of its cancer and immunology drugs. Offerings such as Revlimid, Thalomid and Vidaza combined with prospects such as now-approved Pomalyst are getting investors excited.

>>3 Health Care Stocks Under $10 to Watch

Celgene's pipeline looks strong, despite a lack of diversity in the diseases that the legacy firm's drugs treat. As CELG's researchers come up with new indications for existing therapies, the firm should be able to generate material increases in sales. Growth by acquisition has been a major strategy for management in recent years, adding Abraxis BioScience and Pharmion under the firm's umbrella -- and all of their intellectual property and research capabilities along with it.

From a financial standpoint, Celgene has plenty of dry powder to keep up its strategy. Its $3.5 billion cash position more than offsets a $3 billion debt load, and the firm's true cash generation power is masked by the fact that its $2 billion in annual free cash flow generation has been offset by major investments in recent years. Now the firm has a chance to return extra value to shareholders in 2013. Funds picked up 4.85 million shares of Celgene in the most recent quarter.

5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,014.57 -16.57 -0.10%
S&P 500 1,981.39 -2.74 -0.14%
NASDAQ 4,506.5930 -12.3090 -0.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs